Investor Relations

Press Releases

Date Title/Summary View
Toggle Summary Vericel to Host Third-Quarter 2016 Earnings Webcast and Conference Call on November 7, 2016
CAMBRIDGE, Mass., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What:  Vericel Corporation
View HTML
Toggle Summary Vericel to Present at 2016 Cell & Gene Meeting on the Mesa
CAMBRIDGE, Mass., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, will present at the annual Cell & Gene Meeting on
View HTML
Toggle Summary Vericel to Present at Ladenburg Thalmann Healthcare Conference
CAMBRIDGE, Mass., Sept. 21, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of autologous cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial officer and
View HTML
Toggle Summary Vericel Enters into Expanded $20 Million Credit Facility and Term Loan with Silicon Valley Bank and MidCap Financial Services
CAMBRIDGE, Mass., Sept. 12, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, announced today that it entered into an expanded term loan and revolving line of credit
View HTML
Toggle Summary Vericel to Present Data at the American Heart Association's Scientific Sessions 2016 on the Reduction of Ventricular Arrhythmias with Ixmyelocel-T in the ixCELL-DCM Clinical Trial
CAMBRIDGE, Mass., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of autologous expanded cellular therapies for the treatment of severe diseases and conditions, today announced the acceptance of an abstract for presentation at the American Heart
View HTML
Toggle Summary Vericel Reports Second-Quarter 2016 Financial Results
Total Revenues of $12.8 Million Reported for the Quarter Conference Call Today at 4:30pm Eastern Time CAMBRIDGE, Mass., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of expanded autologous cell therapies for the treatment of severe diseases and conditions,
View HTML
Toggle Summary Vericel to Host Second-Quarter 2016 Earnings Webcast and Conference Call on August 8, 2016
CAMBRIDGE, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call:     What:  Vericel Corporation
View HTML
Toggle Summary Vericel to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
CAMBRIDGE, Mass., July 06, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that Nick Colangelo, president and CEO, and Gerard Michel, chief financial
View HTML
Toggle Summary Vericel Reports First-Quarter 2016 Financial Results
Total Revenues of $14.1 Million Reported for the Quarter Carticel and Epicel Revenues Increase 31% versus First Quarter 2015 Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., May 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific
View HTML
Toggle Summary Vericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced the following webcast and conference call: What: Vericel Corporation
View HTML